The Uterus pp 14-26 | Cite as

Pathophysiology of Diethylstilbestrol Changes

  • Alexander Sedlis
  • Stanley J. Robboy
Part of the Clinical Perspectives in Obstetrics and Gynecology book series (CPOG)


Diethylstilbestrol (DES) and other related nonsteroidal estrogenic substances, e.g., dienestrol and hexestrol, were commonly prescribed for treatment of threatened abortion, toxemia, diabetes, and other pregnancy complications between the 1940s and 1960s. Although the effectiveness of these compounds has never been documented, their use continued until the discovery in 1971 of a link between a clear cell adenocarcinoma of the cervix and vagina and the use of these drugs.1 The impact of this discovery was much wider than just recognition of a new clinical entity. It reaffirmed the dangers of iatrogenic disease and reemphasized the need for proper screening before approval of any drug for treatment.


Squamous Epithelium Squamous Metaplasia Urogenital Sinus Clear Cell Adenocarcinoma Epithelial Change 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Herbst AL, Ulfelder H, Poskanzer DC: Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971;284:878–881.PubMedCrossRefGoogle Scholar
  2. 2.
    Bulmer D: The development of human vagina. J Anat 1957;93:490–509.Google Scholar
  3. 3.
    Robboy SJ: A hypothetic mechanism of diethylstilbestrol (DES)-induced anomalies in prenatally exposed women. Hum Pathol 1983;14:831–833.PubMedCrossRefGoogle Scholar
  4. 4.
    Brenner P, Sedlis A, Cooperman H: Complete imperforate transverse vaginal septum. Obstet Gynecol 1964;25:135–138.Google Scholar
  5. 5.
    Robboy SJ, Noller KL, Kaufman RH, et al: An Atlas of Findings in the Human Female after Intrauterine Exposure to Diethylstilbestrol. NIH Publ no 83–2344. Washington, DC, US Government Printing Office, 1984, 13.Google Scholar
  6. 6.
    Robboy SJ: Changes related to prenatal diethylstilbestrol exposure, in Kurman RJ (ed): Blaustein’s Pathology of the Female Genital Tract, ed 3. New York, Springer-Verlag, 1987; page 121.Google Scholar
  7. 7.
    Herbst AL, Cole P, Colton T, et al: Age-incidence and risk of diethylstilbestrol-related clear cell adenocarcinoma of the vagina and cervix. Am J Obstet Gynecol 1977;128:43–50.PubMedGoogle Scholar
  8. 8.
    Vorherr H, Messer RH, Vorherr UF, et al: Teratogenesis and carcinogenesis in rat offspring after transplacental and transmammary exposure to diethylstilbestrol. Biochem Pharmacol 1977;28:1865–1877.CrossRefGoogle Scholar
  9. 9.
    Stafl A, Mattingly RF: Vaginal adenosis—a precancerous lesion? Am J Obstet Gynecol 1974;120:666–677.PubMedGoogle Scholar
  10. 10.
    Robboy SJ, Noller KL, O’Brien PC, et al: Increased incidence of cervical and vaginal dysplasia in 3,980 diethylstilbestrol exposed young women. JAMA 1984;252:2979.Google Scholar
  11. 11.
    Barnes AB, Colton T, Gundersen JH, et al: Fertility and outcome of pregnancy in women exposed in utero to diethylstilbestrol: Preliminary findings from the DESAD Project. N Engl J Med 1980;302:509–613.CrossRefGoogle Scholar
  12. 12.
    Kaufman RH, Adam E, Binder GL, et al: Upper genital tract changes and pregnancy outcome in offspring exposed in utero to diethylstilbestrol. Am J Obstet Gynecol 1980;137:299–308.PubMedGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1991

Authors and Affiliations

  • Alexander Sedlis
  • Stanley J. Robboy

There are no affiliations available

Personalised recommendations